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Summary
Background The incidence of invasive meningococcal disease in the UK decreased by approximately four times from 
1999 to 2014, with reductions in serogroup C and serogroup B disease. Lower serogroup C invasive meningococcal 
disease incidence was attributable to implementation of the meningococcal serogroup C conjugate vaccine in 1999, 
through direct and indirect protection, but no vaccine was implemented against serogroup B disease. UK 
Meningococcal Carriage surveys 1–3 (UKMenCar1–3), conducted in 1999, 2000, and 2001, were essential for 
understanding the impact of vaccination. To investigate the decline in invasive meningococcal disease incidence, we 
did a large oropharyngeal carriage survey in 2014–15, immediately before the changes to meningococcal vaccines in 
the UK national immunisation schedule.
Methods UKMenCar4 was a cross-sectional survey in adolescents aged 15–19 years who were enrolled from schools and 
colleges geographically local to one of 11 UK sampling centres between Sept 1, 2014, and March 30, 2015. Participants 
provided an oropharyngeal swab sample and completed a questionnaire on risk factors for carriage, including social 
behaviours. Samples were cultured for putative Neisseria spp, which were characterised with serogrouping and whole-
genome sequencing. Data from this study were compared with the results from the UKMenCar1–3 surveys (1999–2001).
Findings From the 19 641 participants (11 332 female, 8242 male, 67 not stated) in UKMenCar4 with culturable swabs and 
completed risk-factor questionnaires, 1420 meningococci were isolated, with a carriage prevalence of 7·23% (95% CI 
6·88–7·60). Carriage prevalence was substantially lower in UKMenCar4 than in the previous surveys: carriage prevalence 
was 16·6% (95% CI 15·89–17·22; 2306/13 901) in UKMenCar1 (1999), 17·6% (17·05–18·22; 2873/16 295) in UKMenCar2 
(2000), and 18·7% (18·12–19·27; 3283/17 569) in UKMenCar3 (2001). Carriage prevalence was lower for all serogroups in 
UKMenCar4 than in UKMenCar1–3, except for serogroup Y, which was unchanged. The prevalence of carriage-promoting 
social behaviours decreased from 1999 to 2014–15, with individuals reporting regular cigarette smoking decreasing from 
2932 (21·5%) of 13 650 to 2202 (11·2%) of 19 641, kissing in the past week from 6127 (44·8%) of 13 679 to 7320 (37·3%) 
of 19 641, and attendance at pubs and nightclubs in the past week from 8436 (62·1%) of 13 594 to 7662 (39·0%) of 19 641 
(all p<0·0001).
Interpretation We show that meningococcal carriage prevalence in adolescents sampled nationally during a low 
incidence period (2014–15) was less than half of that in an equivalent population during a high incidence period 
(1999–2001). Disease and carriage caused by serogroup C was well controlled by ongoing vaccination. The prevalence 
of behaviours associated with carriage declined, suggesting that public health policies aimed at influencing behaviour 
might have further reduced disease.
Funding Wellcome Trust, UK Department of Health, and National Institute for Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Invasive meningococcal disease, caused by Neisseria 
meningitidis, is characterised by meningitis and sepsis 
worldwide, resulting in a rapidly developing, serious 
illness and death in otherwise healthy individuals.1 
N meningitidis is a commensal organism frequently 
carried asymptomatically as part of a healthy 
oropharyngeal microbiota. Rates of carriage vary from 
1–40% of the population depending on age and setting, 
peaking in adolescents and young adults in high-income 
countries.2 The relationship between meningococcal 
carriage and invasive meningo coccal disease was 
systematically investigated in 1917 in military recruits by 
Captain James A Glover,3 who established that periods of 
overcrowding indoors were associated with increased 
meningococcal carriage, which in turn was associated 
with increased incidence of the disease. It has since been 
shown that some meningococci—for example, members 
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of hyper invasive lineages, including those defined as 
clonal complex 11, clonal complex 269, and clonal 
complex 41/44, and certain capsular groups (A, B, C, W, X, 
and Y)—are much more likely to cause disease than 
others and are carried at various rates in the global 
population.4–8 Therefore, it is essential to study carriage 
prevalence and invasive meningococcal disease incidence 
in the context of both serogroup and clonal complex.
Large-scale epidemics of meningococcal disease in the 
UK occurred during the two world wars and the Great 
Depression, with a small outbreak in the 1970s caused by a 
larger global pandemic of serogroup A invasive 
meningococcal disease.9 In the early 1980s, a sustained 
increase in invasive meningococcal disease incidence 
occurred, which peaked in the late 1990s for reasons that 
are incompletely understood (figure 1). Similar to many 
other high-income countries, serogroups B, C, W, and Y 
cause most invasive meningococcal disease in the UK.1 In 
1999, meningococcal serogroup C conjugate (MCC) 
vaccines were introduced in response to an increase of 
serogroup C invasive meningo coccal disease caused by 
clonal complex 11 meningococci (figure 1). The UK 
Meningococcal Carriage (UKMenCar) 1–3 surveys8,11,12 were 
done from 1999 to 2001 to measure the effect of the 
vaccination campaign on meningococcal carriage. These 
studies showed that the MCC vaccine was highly effective 
in reducing transmission of the epidemic meningococci.8,11,12 
Furthermore, these investigations showed that trans-
mission among adolescents (15–19 years), among whom 
the highest carriage prevalence was seen in the UK,2 was 
Research in context
Evidence before this study
Many pharyngeal carriage studies have analysed meningococci 
circulating in the population, and have furthered understanding 
of meningococcal epidemiology and transmission. In high-
income settings, carriage prevalence is highest in adolescents, 
who drive transmission in the wider population. In the UK, 
the success of the meningococcal serotype C conjugate (MCC) 
vaccination programme was, in large part, because of the 
reduction in serogroup C carriage in vaccinated individuals. 
This relationship was investigated by the UK Meningococcal 
Carriage (UKMenCar) 1–3 surveys, cross-sectional carriage 
studies in adolescents done before and after the MCC vaccine 
programme introduction in 1999. These surveys showed MCC 
vaccine-induced herd immunity against the epidemic strain 
(serogroup C, clonal complex 11) among adolescents. 
This herd immunity affected the transmission of clonal 
complex 11 meningococci and protected unvaccinated people. 
Independent of vaccine implementation, the relationship 
between invasive meningococcal disease risk and carriage 
prevalence is complex, varying with several factors, including 
strain types.
We did a literature review up to Feb 19, 2020, to identify studies 
that compared carriage rates between periods of high and low 
disease incidence in countries outside of Africa, where disease 
epidemiology is different to elsewhere. We searched PubMed 
with the Medical Subject Heading terms “meningococcal 
infections” AND “carrier state” AND “incidence” NOT “Africa”, 
which yielded 31 results; five studies were deemed relevant, 
which were in reasonably small populations (ie, not sampled 
nationally). Two studies reported a higher prevalence of carriage 
of the outbreak strain in high-incidence than in low-incidence 
areas, and three studies reported no differences. All languages of 
articles were included.
Added value of this study
The UKMenCar4 study was a large survey of meningococcal 
carriage among adolescents aged 15–19 years in the UK during 
a period of low national incidence of invasive meningococcal 
disease (2014–15). This study is similar to previous studies 
(UKMenCar1–3), which were done with the same methods but 
at a time of high disease incidence. Invasive meningococcal 
disease cases declined steadily between 1999 and 2014, 
including disease caused by serogroups not targeted by the 
MCC vaccine. We showed that adolescent carriage rates more 
than halved, from 16·7–18·7% in 1999–2001 to 7·2% in 
2014–15. Risk factors for carriage were similar between 
UKMenCar1 and UKMenCar4, but adolescent participation in 
these risk factors declined, with fewer students in UKMenCar4 
than in UKMenCar1 reporting active or passive smoking, 
intimate kissing, and attendance at pubs or nightclubs. 
This cross-sectional, observational study also reports baseline 
meningococcal carriage prevalence, stratified by serogroup and 
clonal complex, before the introduction into the UK national 
immunisation schedules of a conjugate polysaccharide vaccine 
against meningococcal serogroups A, C, W, and Y for 
adolescents, and protein-based capsular group B vaccines for 
infants. This long-term ecological study is, therefore, 
a reference point for the UK Be on the Team study (EudraCT 
number 2017–004609–42), a meningococcal carriage survey 
ongoing at the time of writing.
Implications of all the available evidence
This study illustrates the importance of understanding the 
epidemiology of meningococcal carriage in relation to disease 
and the potential for intervention. We showed the long-term 
effects of the MCC vaccine programme, with carriage rates of 
serogroup C meningococci among adolescents decreasing rapidly 
after MCC vaccine implementation and persisting at low levels 
15 years later. Our observation that social behaviour and practices 
known to enhance meningococcal carriage have declined 
alongside carriage prevalence provides a plausible explanation for 
declining rates of the disease. Our results further suggest that 
public health policies aimed at influencing behaviour are likely to 
affect the incidence of invasive meningococcal disease. Assessing 
carriage prevalence is therefore an invaluable marker for assessing 
invasive meningococcal disease risk.
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largely driven by social behaviours such as smoking, 
kissing, and attendance at pubs and nightclubs.13 The 
success of the UK MCC immunisation programme was 
largely attributable to herd protection, with significant and 
specific reduction in the carriage of meningococci from 
genogroup C and clonal complex 11.8,12 In the years after 
implementation of the programme, however, there was 
also a steady decline in the yearly incidence of serogroup B 
invasive meningococcal disease, even though no vaccines 
against serogroup B were put in place for routine use in 
the UK.
The UK has a national health service (NHS) with 
a comprehensive public health disease surveillance 
system, allowing retrospective and prospective analysis of 
invasive meningococcal disease isolates. Since 2010, all 
disease-causing meningococcal isolates have been whole-
genome sequenced by Public Health England (Manchester, 
UK) and the Scottish Microbiology Reference Laboratory 
(Glasgow, UK), with the sequences, deposited in the 
Meningococcal Genome Library.9 In combination with 
large collections of meningococcal carriage isolates, these 
sequence data provided an opportunity to compare 
carriage and disease-causing meningococci between 
periods of high and low incidence. To this end, a 
fourth national carriage survey (UKMenCar4) was done 
among adolescents in the UK to establish the prevalence 
and genetic diversity of carried meningococci in 
2014–15, during which time there was a low incidence of 
invasive meningococcal disease. At this time, only the 
MCC vaccine was part of the national immunisation 
programme; in August, 2015, the MenACWY vaccine 
replaced the adolescent MCC booster dose for those 
approximately 14 years old, and in September, 2015, the 
four-component meningococcal serogroup B (4CMenB) 
vaccine was introduced into the national infant 
immunisation schedule (figure 1).14
Methods
Study design and participants
UKMenCar4 was a cross-sectional survey of 
meningococcal carriage in adolescents aged 15–19 years 
done from Sept 1, 2014, to March 30, 2015, using methods 
that were similar to those used for the three earlier 
surveys (UKMenCar1–3; figure 1).8,11,12,15 In brief, 
UKMenCar1–3 were cross-sectional surveys of adolescents 
aged 15–19 years attending school or college, with 
sampling before (1999 [UKMenCar1]) or after (2000 
[UKMenCar2] and 2001 [UKMenCar3]) the MCC vaccine 
Figure 1: Invasive meningococcal disease incidence in the England and Wales from 1984–85 to 2016–17, by capsular serogroup
Laboratory-confirmed disease cases, including culture-confirmed and PCR-confirmed disease, are stratified by epidemiological year. Coloured bars represent different 
capsular serogroups measured by dot-blot ELISA or siaD PCR. The lines below the graph show the changes in UK vaccination policy over this period for the MCC 
vaccine, the quadrivalent ACWY polysaccharide conjugate vaccine, and the protein-based vaccine 4CMenB (Bexsero [GlaxoSmithKline, Brentford, UK] is the only 
brand available). The timing of the four UK Meningococcal Carriage surveys are shown in relation to periods of high and low incidence of invasive meningococcal 
disease. Disease incidence data were obtained from the Meningococcal Reference Unit of Public Health England.10 Infant refers to those aged <12 months; toddler 
refers to those aged 12–13 months, and adolescent refers to those aged 13–15 years. *A catch-up campaign was implemented in 2000 to all individuals younger than 


































































































































































UK immunisation policy  MCC (infants)*
 MCC (toddler booster)
 MCC (adolescent booster)
 ACWY (adolescent booster)
 4CMenB Bexsero (infants)
UK Meningococcal Carriage surveys
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was introduced across eight sampling regions8,12 (appendix 
p 1). For the earlier surveys, an oropharyngeal swab was 
obtained from each participant for microbiological 
culture confirmation of meningococcal carriage,8,12 and 
each participant completed a questionnaire to identify 
risk factors associated with carriage of N meningitidis13 
(appendix pp 11, 12). For UKMenCar4, all adolescents 
aged 15–19 years who were attending school or 
college years 12 or 13, or equivalent, local to one of 
11 sampling centres across the UK were eligible for 
inclusion (appendix p 1). Written informed consent was 
obtained from all study participants. Study participants 
were invited to provide an oropharyngeal swab for 
microbiological culture and whole-genome sequencing 
(WGS) analysis and to complete a risk factor questionnaire 
(appendix p 13).15 Questionnaires were excluded if 
essential data (identifier and age) were incomplete, or if 
valid consent was not obtained. The Office of National 
Statistics data was used to assess representativeness of 
the sampled population compared with the national 
population (appendix p 6). The study was approved 
under NHS Research Ethics Committee (reference 
number 14/SC/1163).
Specimen collection, microbiological culture, and 
phenotypic characterisation
Laboratory protocols were replicated from the 
UKMenCar1–3 studies8,12 to ensure direct comparability of 
the results of those surveys with the results of 
UKMenCar4.15 Students were recruited and the oropharynx 
of each participant was sampled with cotton or flocked 
swabs and cultured at each centre. The students then 
completed the questionnaire at school in clinics run by 
research staff. Swab samples were either plated directly 
onto selective media or placed in skim milk, tryptone, 
glucose, and glycerol (STGG) broth, and then all samples 
were sent to a microbiology laboratory at the local sampling 
centre for culture, storage, and later laboratory processing. 
If swabs placed into STGG broth could not be plated in the 
laboratory within 4 h they were frozen at –80°C, then 
thawed and cultured as soon as laboratory capacity allowed. 
After growth on selective media at 37°C and 5% CO2 for 
16–24 h, a single colony with morphology typical of 
Neisseria spp was subcultured onto Columbia blood agar 
for a further 16–24 h at 37°C and 5% CO2. Candidate 
Neisseria spp were characterised by Gram staining and 
oxidase tests, and putative meningococci (Gram-negative, 
oxidase-positive diplococci) were stored at –80°C in brain 
heart infusion broth supplemented with glycerol.15 Other 
organisms were not systematically characterised. All 
Gram-negative, oxidase-positive diplo cocci were sent from 
the individual sampling centres to the Public Health 
England Meningococcal Reference Unit (Manchester, UK) 
for phenotypic (serological) characterisation of disease-
associated serogroups (B, C, W, and Y).16
WGS and genomic analysis
All Gram-negative, oxidase-positive diplococci underwent 
DNA extraction with the Qiagen DNeasy Blood & Tissue 
kit (Qiagen, Crawley, UK) at the Public Health England 
Meningococcal Reference Laboratory. High-quality, 
quantified chromosomal DNA underwent WGS at the 
Oxford Genomics Centre (Wellcome Trust Centre for 
Human Genetics, University of Oxford, Oxford, UK) 
using the HiSeq Illumina platform and validated 
protocols.
Short-read sequence data were assembled with Velvet 
version 1.2.10 or VelvetOptimiser software version 2.2.417 
(Department of Zoology, University of Oxford, Oxford, 
UK). The assembled high-quality draft genomes were 
uploaded onto PubMLST and annotated with Neisseria spp 
locus tag identifiers for more than 2400 individual 
loci using the automated BIGSdb software platform.18 
Analysis with a gene-by-gene approach resulted in 
identification of Neisseria species by ribosomal multi-
locus sequence typing (rMLST),19 capsular genogroup 
(identified by capsule-specific alleles),6 and clonal 
Figure 2: Carriage rates and odds ratios for carriage by age
(A) Oropharyngeal carriage rates for adolescents aged 15–19 years in the 
UK for UKMenCar1 in 1999 (2306 meningococci isolates from 
13 901 participants) and UKMenCar4 in 2014–15 (1420 meningococci isolates 
from 19 641 participants). The p values for the difference between the two 
surveys are p=0·00027 for the 15-year-old age group and p<0·0001 for all 
other age groups. (B) Odds ratios for carriage by age in the two carriage 
surveys; the data are also presented in appendix p 7. UKMenCar=UK 
Meningococcal Carriage.













































For the VelvetOptimiser 
software see https://github.
com/tseemann/VelvetOptimiser
See Online for appendix
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complex by MLST.20 The participants’ risk factor data were 
linked by participant identifier to their meningococcal 
genome on the PubMLST database isolate record. For 
UKMenCar1–3 surveys, genomic data were available from 
PCR amplification and direct nucleotide sequencing of 
MLST loci and capsular genes (siaD) and are available in 
the PubMLST database.12
Statistical analysis
Previous multivariate analysis from the UKMenCar1–3 
studies was used to identify risk factors and confounders 
(cigarette smoking; household exposure to cigarette smoke; 
intimate kissing; and socialising at pubs, clubs, and 
parties). For the power calculations, we estimated that a 
sample size of 18 000 participants was needed to provide 
85% power to estimate the prevalence of rare strains. The 
sample size of the study was established by the ability to 
detect rare meningococcal strains (defined here as strains 
with a 1% prevalence). Assuming a 17% overall carriage 
prevalence (based on UKMenCar1–3), with 18 000 parti-
cipants, we would expect to detect 3060 meningococci in 
total, and for rare strains at 1%, we would have a reasonably 
precise 95% CI of 0·85–1·15%. Data are presented for 
UKMenCar4 alongside the results from the UKMenCar1–3 
surveys to enable comparison. Odds ratios (ORs), with two-
sided 95% CIs, were calculated to compare carriage rates by 
age between 1999 (pre-MCC vaccine) and 2014–15. We 
estimated the point prevalence for each Neisseria spp, 
meningococcal serogroup, genogroup, and clonal complex 
with 95% CIs. Weighted proportions represent the carriage 
(%) by demographic stratum. Proportions were compared 
with χ² or Fisher’s exact tests. Prevalence ratios, with 
two-sided 95% CIs, were calculated to compare the 
populations of menin gococci between 2014–15 and 1999 
with respect to genogroup and pro portions expressing 
capsules. Behavioural risk factors associated with 
meningococcal adolescent carriage were analysed with the 
use of univariate logistic regression. All analyses were done 
with R (version 3.5.2) and Stata (version 14).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
Figure 3: Association between adolescent meningococcal carriage prevalence and invasive disease incidence
Bars indicate the measured carriage prevalence of meningococci in adolescents from UKMenCar1 (1999; 13 901 participants), UKMenCar2 (2000; 16 295 participants), UKMenCar3 
(2001; 17 569 participants), and UKMenCar4 (2014–15; 19 641 participants; appendix p 9). Lines indicate England and Wales incidence (per 100 000 population) of invasive meningococcal disease 
caused by each genogroup over time. The predominant carried meningococcal clonal complexes in UKMenCar1–3 and UKMenCar4 are shown. The y-axes for genogroup B are scaled differently 
compared with those of the other genogroups to present the data more clearly. Disease incidence data were obtained from the Meningococcal Reference Unit of Public Health England.10 



















7·50 cc41/44 34·7% (1026 of 2959)
cc213 25·1% (744 of 2959)
cc213 28·9% (100 of 346)
cc41/44 24·9% (86 of 346)
cc22 92·7% (959 of 1035)
cc11 0·5% (5 of 1035)
cc11 71·7% (71 of 99)
cc22 28·3% (28 of 99)
cc11 22·4% (72 of 322)
cc41/44 19·9% (64 of 322)
cc269 36·4% (4 of 11)
cc11 0% (0 of 11)
cc167 40·6% (352 of 867)
cc23 37·5% (325 of 867)
cc23 84·0% (293 of 349)
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access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between Sept 1, 2014, and March 30, 2015, 21 893 students 
were recruited across 11 UK centres. Oropharyngeal 
swabs were prepared for culture from 21 726 eligible 
students, of which 2085 participants’ swabs were 
excluded as they were unable to be processed after 
shipping (n=467) or they were stored in incorrectly 
manufactured STGG broth (n=1618; appendix p 2). In 
total, 19 641 students’ swabs and their corresponding 
risk-factor questionnaires were included in the analysis. 
The demographic characteristics of these students are 
summarised in the appendix (p 6). The proportion of 
the UK national birth cohort in school years 12 and 13 
who were enrolled into UKMenCar4 was 1·74%; this 
sample was representative demographically of the 
entire population of that age in the UK in 2014–16 
(appendix p 6).
Of 19 641 participants, 1420 had N meningitidis isolated, 
246 had putative Neisseria spp isolated, and 17 975 had no 
Neisseria spp isolated (appendix p 2). Carriage prevalence of 
meningococci was 7·23% (95% CI 6·88–7·60; 1420/19 641) 
in UKMenCar4, 16·6% (95% CI 15·89–17·22; 2306/13 901) 
in UKMenCar1 (1999), 17·6% (17·05–18·22; 2873/16 295) 
in UKMenCar2 (2000), and 18·7% (18·12–19·27; 
3283/17 569) in UKMenCar3 (2001). Rates for the individual 
centres ranged from 1·5% to 13·1% (appendix pp 3–4), 
with variation between centres similar to that observed in 
UKMenCar1–3. Neisseria lactamica was carried by 
225 (1·15%, 95% CI 1·00–1·30) of 19 641 participants in 
UKMenCar4, compared with 132 (0·95% 0·80–1·12) 
of 13 901 in 1999. Other commensal Neisseria spp confirmed 
by ribosomal MLST included Neisseria subflava (15 isolates; 
carriage prevalence (0·08%, 95% CI 0·04–0·12), Neisseria 
polysaccharea (three isolates; 0·02%, 0·004–0·040), 
Neisseria cinerea (two isolates; 0·01%, 0·002–0·030), and 
Neisseria bergeri (one isolate, (0·005%, 0·0003–0·0300). 
41 (0·21%) of 19 641 swabs with putative Neisseria spp could 
not be re-cultured for serological testing or DNA extraction 
for WGS, so they are not included in the putative Neisseria 
spp isolates.
Meningococcal carriage rate by age group showed an 
increasing trend from 15 years old to 18–19 years old, both 















p value for 
2014–15 vs 
2001
Total meningococci 2306 (16·6%) 2873 (17·6%) 3283 (18·7%) 1420 (7·2%) 0·44 (0·41–0·46) 0·39 (0·36–0·41) <0·0001
Serogroup B ·· ·· ·· ·· ·· .. ··
Genogroup 785/2306 (34·0%) 994/2873 (34·6%) 1180/3283 (35·9%) 346/1420 (24·4%) 0·72 (0·64–0·80) 0·68 (0·61–0·75) <0·0001
Capsule expression (% of total) 537/2306 (23·3%) 661/2873 (23·0%) 794/3283 (24·2%) 193/1420 (13·6%) 0·58 (0·50–0·68) 0·56 (0·49–0·65) <0·0001
Capsule expression (% of 
genogroup)
537/785 (68·4%) 661/994 (66·5)% 794/1180 (67·3%) 193/346 (55·8%) ·· ·· ··
Serogroup C ·· ·· ·· ·· ·· ·· ··
Genogroup 139/2306 (6·0%) 92/2873 (3·2%) 91/3283 (2·8%) 11/1420 (0·8%) 0·13 (0·07–0·24) 0·26 (0·15–0·52) <0·0001
Capsule expression (% of total) 58/2306 (2·5%) 21/2873 (0·7%) 16/3283 (0·5%) 1/1420 (0·1%) 0·03 (0·00–0·20)  0·14 (0·02–1·09) 0·055
Capsule expression (% of 
genogroup)
58/139 (41·7%) 21/92 (22·8%) 16/91 (17·6%) 1/11 (9·1%) ·· ·· ··
Serogroup W ·· ·· ·· ·· ·· ·· ··
Genogroup 242/2306 (10·5%) 379/2873 (13·2%) 414/3283 (12·6%) 99/1420 (7·0%) 0·66 (0·53–0·83) 0·55 (0·45–0·68) <0·0001
Capsule expression (% of total) 146/2306 (6·3%) 217/2873 (7·6%) 236/3283 (7·2%) 78/1420 (5·5%) 0·87 (0·66–1·13) 0·76 (0·60–0·98) 0·052
Capsule expression (% of 
genogroup)
146/242 (60·3%) 217/379 (57·3%) 236/414 (57·0%) 78/99 (78·8%) ·· ·· ··
Serogroup Y ·· ·· ·· ·· ·· ·· ··
Genogroup 239/2306 (10·4%) 300/2873 (10·4%) 328/3283 (10·0%) 349/1420 (24·6%) 2·37 (2·04–2·76) 2·46 (2·14–2·82) <0·0001
Capsule expression (% of total) 131/2306 (5·7%) 163/2873 (5·7%) 184/3283 (5·6%) 261/1420 (18·4%) 3·24 (2·65–3·95) 3·28 (2·74–3·92) <0·0001
Capsule expression (% of 
genogroup)
131/239 (54·8%) 163/300 (54·3%) 184/328 (56·1%) 261/349 (74·8%) ·· ·· ··
Capsule null ·· ·· ·· ·· ·· ·· ··
Genogroup 369/2306 (16·0%) 534/2873 (18·6%) 622/3283 (18·9%) 328/1420 (23·1%) 1·44 (1·26–1·65) 1·22 (1·08–1·37) 0·009
Other (including serogroups E, H, L, 
W/Y, X, and Z)
·· ·· ·· ·· ·· ·· ··
Genogroup 532/2306 (23·1%) 574/2873 (20·0%) 643/3283 (19·7%) 287/1420 (20·2%) 0·87 (0·77–1·00) 1·03 (0·91–1·17) 0·715
Data are n/N (%), unless otherwise indicated. Serogroup was established for capsular groups B, C, W, and Y only. Other genogroups included: E, n=177; H, n=1; L, n=3; W/Y, n=4; X, n=20; and Z, n=32 in 
UKMenCar4. For UKMenCar1–3, the rates of other individual genogroups were not established. UKMenCar=UK Meningococcal Carriage.
Table: Meningococcal carriage rates in adolescents aged 15–19 years in the UKMenCar1–4 surveys
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however, the age-specific carriage rates were significantly 
lower in UKMenCar4 in every age group than in 
UKMenCar1 (1999), reflecting the overall decline in carriage 
(figure 2A). The age-specific ORs for carriage were similar 
for each age group between 1999 and 2014–15, and ORs 
increased with increasing age (figure 2B, appendix p 7).
Capsular genogroup was identified from WGS data 
for 1370 (96%) of 1420 meningococci, of which all but 
one (<1%) were concordant with the phenotypic 
serogroup result, available in the PubMLST database.12 
The measured UK carriage prevalence, from 19 641 
eligible participants, by genogroup was 1·76% (95% CI 
1·58–1·96; n=346) for genogroup B, 0·06% (0·03–0·10; 
n=11) for genogroup C, 0·50% (0·41–0·61; n=99) for 
genogroup W, 1·78% (1·60–1·97; n=349) for 
genogroup Y, 1·67% (1·50–1·86; n=328) for capsule 
null, and 0·90% (0·77–1·04; n=177) for genogroup E. 
Measured carriage prevalence for disease-causing 
genogroups decreased between 2001 and 2014–15 
for genogroups B, C, and W, whereas genogroup Y 
prevalence did not change (figure 3; appendix p 9). The 
carriage prevalence of genogroup C reduced by 94%, 
from 1·00% (139/13 901) of meningococci in 1999 to 
0·06% (11/19 641) in 2014–15.
The composition of carried meningococcal populations 
changed over time. As a proportion of the carried isolates 
identified, decreases were observed in genogroups B, C, 
and W between 2001 and 2014–15 (table). Increases were 
observed in the proportion of isolates that were genogroup 
Y and capsule null. Serogrouping (phenotypic) methods 
found that the proportion of meningococci in UKMenCar4 
expressing capsule was 78·8% of geno group W, 74·8% of 
genogroup Y, 55·8% of genogroup B, and 9·1% of 
genogroup C (table).
Meningococcal isolates belonged to 29 clonal com-
plexes, with clonal complexes for 94 (7%) of 1420 iso lates 
not categorised because of incomplete MLST profiles or 
belonging to sequence types not yet assigned to clonal 
complexes (appendix p 5). Nine clonal complexes 
accounted for 1066 (75%) of 1420 iso lates (figure 4), 
with measured carriage prevalence in 19 641 samples 
of 1·53% (95% CI 1·37–1·71; n=301) for clonal complex 
23, 0·79% (0·68–0·92; n=156) for clonal complex 1157, 
0·65% (0·55–0·77; n=128) for clonal complex 53, 
0·59% (0·49–0·71; n=116) for clonal complex 41/44, 
0·51% (0·42–0·62; n=101) for clonal complex 213, 0·51% 
(0·42–0·62; n=100) for clonal com plex 198, 0·37% 
(0·29–0·47; n=73) for clonal complex 11, 0·26% 
(0·20–0·34; n=52) for clonal complex 269, and 0·17% 
Figure 5: Risk factors for carriage among UK adolescents in UKMenCar1–4
(A) Meningococcal carriage rates by frequency of risk factors in UKMenCar1, 
the adolescent UK carriage survey done in 1999 (n=13 919). Figure reproduced 
unchanged under CC BY.13 (B) Meningococcal carriage rates by frequency of risk 
factors in UKMenCar4, the adolescent UK carriage survey done in 2014–15 
(n=19 641). Visits to pubs or nightclubs were categorised differently between 
UKMenCar1 and UKMenCar4. UKMenCar=UK Meningococcal Carriage.
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Figure 4: Distribution of meningococcal clonal complexes in 
UKMenCar1–4 surveys
Proportions of the nine most frequently occurring clonal complexes of 
meningococci are shown for the four UKMenCar studies. A clonal complex 
was assigned to 2102 of 2306 meningococci in UKMenCar1, 2692 of 2873 in 
UKMenCar2, 3109 of 3283 in UKMenCar3, and 1326 of 1420 in UKMenCar4. 
cc=clonal complex. UKMenCar=UK Meningococcal Carriage.
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(0·12–0·24; n=33) for clonal complex 22. The relative 
carriage prevalence of certain clonal complexes changed 
over time: clonal complexes 23, 1157, 198, and 11 
increased from UKMenCar1 to UKMenCar4 (all p<0·001; 
appendix p 10; figure 4). Of the hyperinvasive lineages, 
clonal complex 23 had a relative carriage prevalence ratio 
(2014–15 to 1999) of 5·37 (95% CI 4·29–6·73) and clonal 
complex 11 had a ratio of 2·76 (1·90–4·00). Significant 
reductions were observed in the relative carriage 
prevalence (2014–15 to 1999) of clonal complexes 41/44 
(rate ratio 0·54, 95% CI 0·44–0·66) and 22 
(0·20, 0·14–0·28) meningococci from UKMenCar1 to 
UKMenCar4.
Invasive meningococcal disease incidence measured 
across all age groups, changed from 1999 to 2014–15 
for each disease-associated serogroup, coincident with 
fluctuations in clonal complex distribution (figure 4) and 
adolescent carriage of these clonal complexes (figure 3). 
Serogroup B invasive meningococcal disease steadily 
declined from 1999 to 2014–15, with a shift in the 
predominant clonal complex carried by adolescents 
from clonal complex 41/44 to clonal complex 213 
(figure 4). Rates of group C invasive meningococcal 
disease declined rapidly after MCC introduction in 1999, 
coincident with a decrease in genogroup C carriage and 
elimination from carriage of genogroup C clonal 
complex 11 by 2014–15 (figure 3). For genogroup W, the 
predominant clonal complex carried by adolescents 
switched from clonal complex 22 in UKMenCar1–3 to 
clonal complex 11 in UKMenCar4 (figure 3), which 
was coincident with increasing serogroup W disease 
(figure 1 and 3). For genogroup Y, the predominant 
clonal complex in UKMenCar4 was clonal complex 23, 
whereas clonal complex 167 predominated in 1999 
(figure 3).
The proportion of adolescents self-reporting as 
regular smokers decreased by 47·9% from 1999 (21·5%; 
2932/13 650) to 2014–15 (11·2%; 2202/19 641; p<0·0001), 
although the small proportion of heavy smokers 
(>20 cigarettes per day) was unchanged (0·3%, 46/13 650 
in 1999 vs 0·3%, 55/19 641 in 2014–15; p=0·41). Reporting 
of intimate kissing in the previous week reduced by 
16·7% from 1999 (44·8%; 6127/13 679) to 2014–15 
(37·3%; 7320/19 641; p<0·0001), with fewer adolescents 
reporting multiple (more than one) partners in 2014–15 
(4·6%; 904/19 641) than from 1999 (18·9%; 122/13 679; 
p<0·0001). Attendance at pubs and nightclubs fell by 
37·2% in 1999 (62·1%; 8436/13 594) to 2014–15 (39·0%; 
7662/19 641; p<0·0001). A cumulative pattern of risk 
factors was associated with higher carriage (figure 5), 
with adolescents who reported smoking, kissing, and 
visiting pubs or nightclubs more frequently having up to 
a five times higher risk of carriage than adolescents who 
did not participate in those activities. Similar to the odds 
ratios for carriage by age (figure 2B), the behavioural risk 
factors did not change; rather the prevalence of these 
behaviours changed (figure 5).
Discussion
UKMenCar1–4 enabled the investigation of meningococcal 
epidemiology in the UK, providing national, cross-sectional 
estimates of carriage prevalence in adolescents, enabling 
the observation of changes over time of genotype 
replacement, and to facilitate the assessment of the effects 
of meningococcal vaccine programmes. UKMenCar4 
additionally provided definitive molecular characterisation 
of meningococci carried by UK adolescents in 2014–15.
From 1999 to 2015, the incidence of invasive meningo-
coccal disease in the UK declined, from 1856 laboratory-
confirmed cases in England in 2001–02 to 724 in 2014–15, 
a 61% reduction.21 Older adolescents generally have the 
highest rates of meningococcal carriage among countries 
with similar epidemiology to western Europe.2 The 
UKMenCar4 survey identified a 61% reduction in 
measured carriage prevalence among UK adolescents 
since 2001, providing a potential explanation for the 
decrease in invasive meningococcal disease, because of 
the disruption of meningococcal transmission.22
These data are consistent with the long-term effective-
ness of the MCC national immunisation programme. 
During the UKMenCar1–3 surveys, a significant reduction 
in carriage of genogroup and serogroup C meningococci 
was attributed to effects of the MCC vaccine.8,11–13 In the 
UKMenCar4 survey, genogroup C meningococci occurred 
at a low frequency and genogroup C, clonal complex 11 
meningococci were not identified, probably because of 
the combined effects of the MCC vaccine and reduction 
in carriage-promoting behaviours among adolescents. 
However, a degree of transmission persisted in the wider 
community as 28 cases of serogroup C invasive menin-
gococcal disease were reported to Public Health England 
in 2014–15.21 Data from the Meningococcal Genome 
Library9 showed that of the 23 serogroup C isolates with 
sequencing data, 16 (70%) were clonal complex 11. 
This finding shows the importance of ongoing, real-time 
surveillance using national collections of invasive 
meningococcal disease genomes for assessing vaccination 
programmes.
With respect to hyperinvasive lineages, the relative 
carriage prevalence of genogroup C, clonal complex 11 in 
UKMenCar1 (1999) was low (1·5%),12 despite high 
rates of disease caused by this genotype. These data 
contrast with the relative carriage prevalence of 5·0% 
for genogroup W, clonal complex 11 in UKMenCar4 
(2014–15), a strain that was associated with a national 
increase in serogroup W invasive meningococcal disease 
from 2009.23 Furthermore, 79% of genogroup W meningo-
cocci isolated in 2014–15 expressed a capsule, a proportion 
that was higher than those for genogroups B, C, and Y 
meningococci in 2014–15, but similar to that of genogroup 
C, clonal complex 11 in 1999 (81%),12 a factor 
probably contributing to the invasive potential of these 
meningococci. The rapid clonal expansion of genogroup 
W, clonal complex 11 was coincident with reductions in 
the carriage of genogroup W, clonal complex 22, which 
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has a low disease potential.4 Increasing circulation of 
genogroup W, clonal complex 11 meningococci had a 
substantial effect on the incidence of serogroup W 
invasive meningococcal disease globally,23,24 and subs-
equent25 vaccine policies in Australia (imple mented in 
February, 2019), the Netherlands (implemented in 
October, 2018), and the UK (implemented in August, 
2015) have largely targeted adolescents because they are 
the highest carriers of meningococci,14,24,26 and we have 
found high rates of carriage of genogroup W, clonal 
complex 11 in them. This study reinforces that the decision 
to vaccinate adolescents to protect the wider population 
against genogroup W, clonal complex 11 disease was 
justified.
A steady decrease in the total number of cases of 
serogroup B invasive meningococcal disease in England—
from 1495 cases in 1999–2000 to 418 cases in 2014–15 
(a 72·0% reduction)—occurred in the absence of an 
effective vaccination programme targeting serogroup B 
meningococci in the UK. By comparison, there was a 
96·7% reduction in cases of serogroup C invasive 
meningococcal disease over the same period following 
MCC vaccine introduction.21 We observed a 69% reduction 
in genogroup B carriage prevalence among adolescents 
between UKMenCar1 and UKMenCar4; this reduction 
probably contributed to reductions in sero group B invasive 
meningococcal disease in both children younger than 
5 years and adolescents, both groups at a high risk of the 
disease.22 Additional factors for the declining incidence of 
serogroup B invasive meningococcal disease include the 
reduction in the carriage of hyperinvasive clonal complex 
41/44, with relative increases in clonal complexes with 
lower invasive potential,4 and a lower proportion of 
meningococci expressing capsule. In 2019, the global 
burden of serogroup B invasive meningococcal disease 
was low,5 with evidence of declining incidence rates 
worldwide27 often in the absence of vaccination pro-
grammes. This decrease implicates secular changes in the 
circulation of hyperinvasive serogroup B menin gococci, 
as shown in the UK (figure 3), as a reason for reduced 
disease rates (figure 1). The protein-based 4CMenB 
vaccine Bexsero was introduced into the infant 
immunisation programmes in Andorra, Ireland, Italy, 
Lithuania, and the UK to provide direct protection to this 
susceptible group.24 There was no evidence of herd 
immunity induced by the 4CMenB vaccine to disease-
causing serogroups (B, C, W, or Y) in an Australian 
intervention study,28 and at the time of writing, a large-scale 
UK carriage study was further investigating herd immunity 
for both licenced protein-based vaccines (EudraCT 
number 2017-004609-42). In the absence of any evidence 
of herd effects, it might not be cost-effective to immunise 
adolescents. Therefore, identifying other less costly 
interventions might be necessary.
Increasing incidence of serogroup Y invasive menin-
gococcal disease was reported to Public Health England 
from 2011–12 to 2019, particularly affecting the older (aged 
65 years or older) population. In UKMenCar4, genogroup Y, 
clonal complex 23 meningo cocci had replaced the less 
invasive genogroup Y, clonal complex 167 meningococci 
and genogroup Y, clonal complex 22 meningococci that 
were present in UKMenCar1–3. Indirect protective effects 
of conjugate polysaccharide vaccines were observed with 
the MCC vaccine globally and with the serogroup A vaccine 
in the African meningitis belt (MenAfriVac).29 The 
quadrivalent, conjugate polysaccharide MenACWY vaccine 
might prevent the acquisition of meningococci,30 thereby 
reducing onwards transmission, which could reduce the 
increasing rates of serogroup Y invasive meningococcal 
disease in the UK via inclusion of the vaccine in the 
adolescent programme introduced in 2015.14
We observed changes in adolescent behaviour between 
UKMenCar1 and UKMenCar4, although the incremental 
increase in risk of carriage with increasing age and age-
associated odds ratios for carriage were similar between 
1999 and 2014–15. The decline in adolescent carriage 
prevalence between 1999 and 2014–15 was concomitant 
with measurable changes in adolescent social inte-
ractions. The UKMenCar4 survey identified reduced 
participation in carriage-promoting activities, such as 
smoking, kissing, and attending pubs and nightclubs, 
compared with UKMenCar1. Changing adolescent 
behaviour in the UK has been observed in the declining 
rates of smoking, sexual intercourse, pregnancy, and 
new sexually transmitted infections reported in national 
surveillance studies31,32 and two large contemporaneous 
birth cohorts.33 There were major social and policy 
changes over this period, including the introduction of a 
national smoking ban (2006–07), more rigorous identity 
checks for admission into pubs and nightclubs, and 
increased use of mobile telephones and social media, 
resulting in less direct interpersonal contact. All these 
influences on adolescent behaviour are likely to affect the 
transmission of meningococci between hosts, which is a 
prerequisite to invasive disease. Behavioural changes 
might, therefore, have effects on the incidence of 
invasive meningococcal disease, alongside other targeted 
interventions, including vaccination.
These four UKMenCar surveys were cross-sectional, 
the most appropriate study design to estimate carriage 
pre valence in the absence of an intervention or control 
group. All four UK carriage surveys were done with the 
same microbiological methods for identification of 
meningococci, allowing comparisons of results.8,11–13 The 
molecular methods to derive nucleotide sequence data 
for the characterisation of MLST loci and geno group 
were technically different between UKMenCar1–3 and 
UKMenCar4. From retro spective WGS of 498 UKMenCar1 
isolates, there were 13 (3%) isolates with MLST dis-
crepancies between PCR-based sequencing and WGS 
(data not shown). In all four surveys, regional variability 
was observed among sampling centres (appendix pp 3–4), 
but these surveys included broadly equivalent populations 
(appendix pp 6, 8) and consistent study design. Although 
For the be on the TEAM study 
see https://beontheteam.web.
ox.ac.uk/home
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2085 (9·6%) of 21 726 swabs could not be cultured and 
were excluded for technical reasons, overall recruitment 
excluding these swabs (19 641 participants) exceeded the 
sample size of 18 000 on which the study was powered. 
Additionally, 41 putative Neisseria spp isolates were 
excluded as they could not be re-cultured for further 
serological or genomic analysis, and because we could 
not confirm their species, they could not contribute 
to carriage estimates. N lactamica, a closely related 
oropharyngeal commensal organism, has a different 
demographic pattern of carriage and potential risk factors 
to N meningitidis. It was notable that N lactamica carriage 
prevalence was similar between UKMenCar1 and 
UKMenCar4; as a result, the ratio of N meningitidis to N 
lactamica changed from 17:1 (in 1999) to 6:1 (in 2014–15).
Findings of UKMenCar1–4, which were done in periods of 
high and low disease incidence in the UK, are consistent 
with an association between lower incidence of invasive 
meningo coccal disease and lower prevalence of circulating 
meningococci in adolescents, which in turn is associated 
with changing social behaviours. Our observations have 
global implications for modification of public health 
interventions and vaccine policy to reduce the morbidity and 
mortality resulting from invasive meningococcal disease 
and other pathogens residing in the respiratory tract.
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